Marker Therapeutics, Inc. (MRKR) stock
MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.87−0.03 (-3.33%)
Close on Nov 13, 2026Market cap $14.51MP/E –Yield –
Marker Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Marker Therapeutics's ebitda for the twelve months ending Mar 31, 2023 was -$15.41M. For fiscal 2022 it was -$17.00M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$17.00M | – |
| FY2021 | Dec 31, 2021 | -$37.33M | – |
| FY2020 | Dec 31, 2020 | -$28.40M | – |
| FY2019 | Dec 31, 2019 | -$22.42M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2023 | Mar 31, 2023 | -$3.49M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.23M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.01M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.20M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.47M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.30M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.23M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.61M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.33M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.62M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.63M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.67M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.20M | – |
See a number that looks wrong?